Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.63M Buy
+8,600
New +$1.28M ﹤0.01% 3372
2025
Q4
Sell
-2,800
Closed -$273K 4561
2025
Q3
$273K Buy
+2,800
New +$226K ﹤0.01% 4155
2025
Q2
Sell
-6,900
Closed -$343K 4312
2025
Q1
$343K Buy
+6,900
New +$436K ﹤0.01% 3702
2024
Q1
Sell
-23,300
Closed -$3.02M 4294
2023
Q4
$3.02M Sell
23,300
-35,700
-61% -$4.92M ﹤0.01% 2330
2023
Q3
$9.62M Buy
59,000
+22,100
+60% +$3.89M 0.01% 1313
2023
Q2
$6.76M Buy
36,900
+26,900
+269% +$3.87M 0.01% 1648
2023
Q1
$1.33M Buy
+10,000
New +$1.17M ﹤0.01% 2966

Other funds holding ACLS

David Shaw's ACLS Position: Q2 2026 in Review

David Shaw reduced its Axcelis (ACLS) stake by 76% in Q2 2026, selling an estimated $61M and leaving 133,044 shares worth $25.2M. The position accounts for 0.01% of the portfolio, ranked #1139.

David Shaw first reported a position in ACLS in Q2 2013 and has held it in 41 quarters since. The position peaked at $50.7M in Q1 2026. 439 funds tracked by Wall St. Rank hold ACLS as of Q2 2026.

  • David Shaw held 133,044 shares of Axcelis worth $25.2M as of Q2 2026.
  • David Shaw sold 411,377 Axcelis shares in Q2 2026, an estimated $61M.
  • Axcelis made up 0.01% of David Shaw's portfolio in Q2 2026, its #1139 holding.
  • David Shaw first reported a position in Axcelis in Q2 2013 and has held it in 41 quarters since.
  • David Shaw's Axcelis position peaked at $50.7M in Q1 2026.
  • 439 funds tracked by Wall St. Rank held Axcelis as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.